Biological Significance of Anti-SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy.
Identifieur interne : 000100 ( Main/Exploration ); précédent : 000099; suivant : 000101Biological Significance of Anti-SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy.
Auteurs : Navid Manouchehri ; Lawrence Steinman ; Olaf Stuve [États-Unis]Source :
- Neurology(R) neuroimmunology & neuroinflammation [ 2332-7812 ] ; 2021.
Descripteurs français
- KwdFr :
- Anticorps antiviraux (immunologie), Humains (MeSH), Immunité acquise (immunologie), Immunité humorale (immunologie), Leucoencéphalopathie multifocale progressive (immunologie), Leucoencéphalopathie multifocale progressive (traitement médicamenteux), Lymphocytes T (immunologie), Production d'anticorps (immunologie).
- MESH :
- immunologie : Anticorps antiviraux, Immunité acquise, Immunité humorale, Leucoencéphalopathie multifocale progressive, Lymphocytes T, Production d'anticorps.
- traitement médicamenteux : Leucoencéphalopathie multifocale progressive.
- Humains.
English descriptors
- KwdEn :
- Adaptive Immunity (immunology), Antibodies, Viral (immunology), Antibody Formation (immunology), Humans (MeSH), Immunity, Humoral (immunology), Leukoencephalopathy, Progressive Multifocal (drug therapy), Leukoencephalopathy, Progressive Multifocal (immunology), SARS-CoV-2 (immunology), T-Lymphocytes (immunology).
- MESH :
- chemical , immunology : Antibodies, Viral.
- drug therapy : Leukoencephalopathy, Progressive Multifocal.
- immunology : Adaptive Immunity, Antibody Formation, Immunity, Humoral, Leukoencephalopathy, Progressive Multifocal, SARS-CoV-2, T-Lymphocytes.
- Humans.
Abstract
OBJECTIVE
To discuss the pathogenic and diagnostic relevance of cellular and humoral immune responses against severe acute respiratory syndrome novel coronavirus (SARS-COV-2) and pertinent observations made in progressive multifocal leukoencephalopathy (PML).
METHODS
Review of pertinent literature
CONCLUSION
Based on pathogenic lessons learned from PML under natalizumab therapy, we suggest the incorporation of functional assays that determine neutralizing properties of SARS-CoV-2-specific antibodies. In addition, we outline the potential role of T-cell detection assays in determining herd immunity in a given population or in studying therapeutic responses to vaccines.
DOI: 10.1212/NXI.0000000000000935
PubMed: 33361386
PubMed Central: PMC7768959
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biological Significance of Anti-SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy.</title><author><name sortKey="Manouchehri, Navid" sort="Manouchehri, Navid" uniqKey="Manouchehri N" first="Navid" last="Manouchehri">Navid Manouchehri</name><affiliation><nlm:affiliation>From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center.</nlm:affiliation><wicri:noCountry code="subField">VA Medical Center</wicri:noCountry></affiliation></author><author><name sortKey="Steinman, Lawrence" sort="Steinman, Lawrence" uniqKey="Steinman L" first="Lawrence" last="Steinman">Lawrence Steinman</name><affiliation><nlm:affiliation>From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center.</nlm:affiliation><wicri:noCountry code="subField">VA Medical Center</wicri:noCountry></affiliation></author><author><name sortKey="Stuve, Olaf" sort="Stuve, Olaf" uniqKey="Stuve O" first="Olaf" last="Stuve">Olaf Stuve</name><affiliation wicri:level="1"><nlm:affiliation>From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center. olaf.stuve@utsouthwestern.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33361386</idno><idno type="pmid">33361386</idno><idno type="doi">10.1212/NXI.0000000000000935</idno><idno type="pmc">PMC7768959</idno><idno type="wicri:Area/Main/Corpus">000088</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000088</idno><idno type="wicri:Area/Main/Curation">000088</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000088</idno><idno type="wicri:Area/Main/Exploration">000088</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Biological Significance of Anti-SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy.</title><author><name sortKey="Manouchehri, Navid" sort="Manouchehri, Navid" uniqKey="Manouchehri N" first="Navid" last="Manouchehri">Navid Manouchehri</name><affiliation><nlm:affiliation>From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center.</nlm:affiliation><wicri:noCountry code="subField">VA Medical Center</wicri:noCountry></affiliation></author><author><name sortKey="Steinman, Lawrence" sort="Steinman, Lawrence" uniqKey="Steinman L" first="Lawrence" last="Steinman">Lawrence Steinman</name><affiliation><nlm:affiliation>From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center.</nlm:affiliation><wicri:noCountry code="subField">VA Medical Center</wicri:noCountry></affiliation></author><author><name sortKey="Stuve, Olaf" sort="Stuve, Olaf" uniqKey="Stuve O" first="Olaf" last="Stuve">Olaf Stuve</name><affiliation wicri:level="1"><nlm:affiliation>From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center. olaf.stuve@utsouthwestern.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country></affiliation></author></analytic><series><title level="j">Neurology(R) neuroimmunology & neuroinflammation</title><idno type="eISSN">2332-7812</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptive Immunity (immunology)</term><term>Antibodies, Viral (immunology)</term><term>Antibody Formation (immunology)</term><term>Humans (MeSH)</term><term>Immunity, Humoral (immunology)</term><term>Leukoencephalopathy, Progressive Multifocal (drug therapy)</term><term>Leukoencephalopathy, Progressive Multifocal (immunology)</term><term>SARS-CoV-2 (immunology)</term><term>T-Lymphocytes (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps antiviraux (immunologie)</term><term>Humains (MeSH)</term><term>Immunité acquise (immunologie)</term><term>Immunité humorale (immunologie)</term><term>Leucoencéphalopathie multifocale progressive (immunologie)</term><term>Leucoencéphalopathie multifocale progressive (traitement médicamenteux)</term><term>Lymphocytes T (immunologie)</term><term>Production d'anticorps (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukoencephalopathy, Progressive Multifocal</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunité acquise</term><term>Immunité humorale</term><term>Leucoencéphalopathie multifocale progressive</term><term>Lymphocytes T</term><term>Production d'anticorps</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Adaptive Immunity</term><term>Antibody Formation</term><term>Immunity, Humoral</term><term>Leukoencephalopathy, Progressive Multifocal</term><term>SARS-CoV-2</term><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucoencéphalopathie multifocale progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To discuss the pathogenic and diagnostic relevance of cellular and humoral immune responses against severe acute respiratory syndrome novel coronavirus (SARS-COV-2) and pertinent observations made in progressive multifocal leukoencephalopathy (PML).</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Review of pertinent literature</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Based on pathogenic lessons learned from PML under natalizumab therapy, we suggest the incorporation of functional assays that determine neutralizing properties of SARS-CoV-2-specific antibodies. In addition, we outline the potential role of T-cell detection assays in determining herd immunity in a given population or in studying therapeutic responses to vaccines.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33361386</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2332-7812</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>03</Month></PubDate></JournalIssue><Title>Neurology(R) neuroimmunology & neuroinflammation</Title><ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation></Journal><ArticleTitle>Biological Significance of Anti-SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e935</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000000935</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To discuss the pathogenic and diagnostic relevance of cellular and humoral immune responses against severe acute respiratory syndrome novel coronavirus (SARS-COV-2) and pertinent observations made in progressive multifocal leukoencephalopathy (PML).</AbstractText><AbstractText Label="METHODS">Review of pertinent literature<b>.</b> RESULTS: There is at least 1 precedent for an antibody response against a viral pathogen that fails to provide host protection in the absence of immune-competent CD4<sup>+</sup> T cells. PML is an infection of the CNS caused by JC virus (JCV), which commonly occurs during treatment with the therapeutic monoclonal antibody natalizumab. In this context, the humoral immune response fails to prevent JCV reactivation, and elevated anti-JCV serum indices are associated with a higher PML incidence. The more relevant immune-competent cells in host defense against JCV appear to be T cells. T cell-mediated responses are also detectable in convalescing patients with SARS-COV-2 irrespective of the humoral immune response.</AbstractText><AbstractText Label="CONCLUSION">Based on pathogenic lessons learned from PML under natalizumab therapy, we suggest the incorporation of functional assays that determine neutralizing properties of SARS-CoV-2-specific antibodies. In addition, we outline the potential role of T-cell detection assays in determining herd immunity in a given population or in studying therapeutic responses to vaccines.</AbstractText><CopyrightInformation>Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manouchehri</LastName><ForeName>Navid</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinman</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stuve</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center. olaf.stuve@utsouthwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA><NlmUniqueID>101636388</NlmUniqueID><ISSNLinking>2332-7812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="N">Adaptive Immunity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007968" MajorTopicYN="N">Leukoencephalopathy, Progressive Multifocal</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>08</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>28</Day><Hour>11</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33361386</ArticleId><ArticleId IdType="pii">8/2/e935</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000935</ArticleId><ArticleId IdType="pmc">PMC7768959</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS Pathog. 2009 Mar;5(3):e1000363</Citation><ArticleIdList><ArticleId IdType="pubmed">19325891</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 Oct 1;183(1):158-168.e14</Citation><ArticleIdList><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2011 Sep;134(Pt 9):2687-702</Citation><ArticleIdList><ArticleId IdType="pubmed">21908874</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Immunol. 2020 Jun 26;5(48):</Citation><ArticleIdList><ArticleId IdType="pubmed">32591408</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2016 Aug 1;197(3):983-93</Citation><ArticleIdList><ArticleId IdType="pubmed">27342848</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2017 Oct 24;12(10):e0186998</Citation><ArticleIdList><ArticleId IdType="pubmed">29065175</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Jul 14;11(1):3581</Citation><ArticleIdList><ArticleId IdType="pubmed">32665645</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7528-32</Citation><ArticleIdList><ArticleId IdType="pubmed">1881893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurovirol. 2001 Aug;7(4):318-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11517410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 30;395(10238):1715-1725</Citation><ArticleIdList><ArticleId IdType="pubmed">32405103</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2020 Aug 14;369(6505):812-817</Citation><ArticleIdList><ArticleId IdType="pubmed">32434946</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 Sep;585(7824):268-272</Citation><ArticleIdList><ArticleId IdType="pubmed">32396922</ArticleId></ArticleIdList></Reference><Reference><Citation>J Intensive Care. 2020 May 24;8:36</Citation><ArticleIdList><ArticleId IdType="pubmed">32483488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Aug 22;396(10250):535-544</Citation><ArticleIdList><ArticleId IdType="pubmed">32645347</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 Aug;584(7821):457-462</Citation><ArticleIdList><ArticleId IdType="pubmed">32668444</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2003 Sep;71(1):115-23</Citation><ArticleIdList><ArticleId IdType="pubmed">12858417</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Nov 12;383(20):1920-1931</Citation><ArticleIdList><ArticleId IdType="pubmed">32663912</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 Jun 25;181(7):1489-1501.e15</Citation><ArticleIdList><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):</Citation><ArticleIdList><ArticleId IdType="pubmed">29500304</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2005 Apr;109(4):449-55</Citation><ArticleIdList><ArticleId IdType="pubmed">15739098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2006 May;59(5):743-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16634029</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Immunol. 1993 Jun;5(6):657-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7688562</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurol Neuroimmunol Neuroinflamm. 2019 Sep 25;6(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">31554671</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12283-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25136134</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2006 Oct;63(10):1383-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17030653</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2017 Nov;16(11):925-933</Citation><ArticleIdList><ArticleId IdType="pubmed">28969984</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 Jul;96:131-135</Citation><ArticleIdList><ArticleId IdType="pubmed">32376308</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2016 Jan 1;183(1):61-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26667254</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2020 Oct 2;370(6512):89-94</Citation><ArticleIdList><ArticleId IdType="pubmed">32753554</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2003 Jun;84(Pt 6):1499-1504</Citation><ArticleIdList><ArticleId IdType="pubmed">12771419</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2016 Aug 1;197(3):994-1002</Citation><ArticleIdList><ArticleId IdType="pubmed">27335502</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1973 Apr;127(4):467-70</Citation><ArticleIdList><ArticleId IdType="pubmed">4571704</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2001 Apr;75(7):3483-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11238876</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurol. 2004 Jun;17(3):365-70</Citation><ArticleIdList><ArticleId IdType="pubmed">15167073</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2020 Jun;20(6):339-341</Citation><ArticleIdList><ArticleId IdType="pubmed">32317716</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Immunol. 1995 Feb;25(2):451-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7875208</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2009 Feb 3;72(5):396-401</Citation><ArticleIdList><ArticleId IdType="pubmed">18987352</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ophthalmol. 1998 Mar;125(3):292-300</Citation><ArticleIdList><ArticleId IdType="pubmed">9512145</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2006 Feb 1;176(3):1951-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16424227</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 1994 Jun;1(3):179-87</Citation><ArticleIdList><ArticleId IdType="pubmed">7889406</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2020 Oct 24;:</Citation><ArticleIdList><ArticleId IdType="pubmed">33228974</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Manouchehri, Navid" sort="Manouchehri, Navid" uniqKey="Manouchehri N" first="Navid" last="Manouchehri">Navid Manouchehri</name><name sortKey="Steinman, Lawrence" sort="Steinman, Lawrence" uniqKey="Steinman L" first="Lawrence" last="Steinman">Lawrence Steinman</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Stuve, Olaf" sort="Stuve, Olaf" uniqKey="Stuve O" first="Olaf" last="Stuve">Olaf Stuve</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000100 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000100 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidStanfordV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33361386
|texte= Biological Significance of Anti-SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33361386" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidStanfordV1
| This area was generated with Dilib version V0.6.38. |  |